UTHR CEO exercises options, sells 9,500 shares
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at a strike price of $146.03 per share and sold 9,500 shares in multiple open-market transactions around $561–$572 per share.
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at a strike price of $146.03 per share and sold 9,500 shares in multiple open-market transactions around $561–$572 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to run until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 9,500 shares ($3.99M approx. pre-tax spread)
Exercise and Sale
18 txns
Insider
ROTHBLATT MARTINE A
Role
Chairperson & CEO
Sold
9,500 shs ($5.37M)
Approx. gross sale proceeds
$5.37M
Approx. exercise cost
$1.39M
Approx. pre-tax spread
$3.99M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 9,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 9,500 | $146.03 | $1.39M |
| Sale | Common Stock | 295 | $561.5263 | $166K |
| Sale | Common Stock | 1,520 | $562.5887 | $855K |
| Sale | Common Stock | 1,638 | $563.6797 | $923K |
| Sale | Common Stock | 1,369 | $564.5903 | $773K |
| Sale | Common Stock | 563 | $565.6928 | $318K |
| Sale | Common Stock | 1,261 | $566.7206 | $715K |
| Sale | Common Stock | 1,339 | $567.7579 | $760K |
| Sale | Common Stock | 728 | $568.7815 | $414K |
| Sale | Common Stock | 227 | $569.5712 | $129K |
| Sale | Common Stock | 260 | $570.7635 | $148K |
| Sale | Common Stock | 300 | $571.5473 | $171K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option — 145,410 contracts (Direct);
Common Stock — 40,513 shares (Direct);
Common Stock — 166 shares (Indirect, by Spouse);
Common Stock — 628,049 shares (Indirect, by Trust)
Footnotes (16)
- F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.
- F10. This transaction was executed in multiple trades at prices ranging from $569.36 to $570.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11. This transaction was executed in multiple trades at prices ranging from $570.41 to $571.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F12. This transaction was executed in multiple trades at prices ranging from $571.54 to $571.65. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F13. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F14. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F15. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F16. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F2. This transaction was executed in multiple trades at prices ranging from $561.00 to $561.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. This transaction was executed in multiple trades at prices ranging from $562.15 to $563.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $563.16 to $564.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $564.16 to $565.155. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $565.25 to $566.12. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $566.30 to $567.29. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $567.31 to $568.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $568.36 to $569.29. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Options exercised: 9,500 shares
Exercise price: $146.03/share
Shares sold: 9,500 shares
+5 more
8 metrics
Options exercised
9,500 shares
Common stock acquired via option exercise on May 28, 2026
Exercise price
$146.03/share
Strike price of exercised stock options
Shares sold
9,500 shares
Open-market sales of common stock on May 28, 2026
Representative sale price
$571.55/share
One reported weighted average sale price for common stock
Plan option capacity
1,734,410 options
Maximum stock options to be exercised under 10b5-1 plan
Plan adoption date
November 7, 2025
Date Rule 10b5-1 trading plan was adopted
Option expiration
March 17, 2027
Expiration date of options referenced in the plan
Plan end date
December 31, 2026
Latest possible end date of the 10b5-1 plan
Key Terms
Rule 10b5-1 trading plan, stock options, weighted average price, family trusts, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"exercise of stock options and sale of the resulting shares of common stock"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
family trusts financial
"Shares held in family trusts as to which the Reporting Person shares investment power"
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did UNITED THERAPEUTICS (UTHR) report for Martine Rothblatt?
UNITED THERAPEUTICS reported that CEO Martine Rothblatt exercised stock options for 9,500 common shares and sold 9,500 shares in open-market trades. The sales occurred at prices around $561–$572 per share under a pre-arranged Rule 10b5-1 trading plan.
What was the strike price of the UNITED THERAPEUTICS (UTHR) stock options exercised?
The exercised stock options had a strike price of $146.03 per share. Exercising these options allowed conversion into 9,500 shares of UNITED THERAPEUTICS common stock, which were then sold in the market according to the disclosed Form 4 transaction details.
How long will the CEO’s UNITED THERAPEUTICS (UTHR) 10b5-1 plan remain in effect?
The Rule 10b5-1 plan will continue until the earlier of two events: exercise of 1,734,410 stock options that expire on March 17, 2027, or December 31, 2026. This sets a clear outer limit on the disclosed trading program’s duration.
What indirect UNITED THERAPEUTICS (UTHR) holdings are reported for the CEO?
The Form 4 lists multiple indirect holdings in UNITED THERAPEUTICS common stock through family trusts and a spouse’s holdings. These entries show shares held where the reporting person or spouse has trustee or investment powers, reflecting broader family-related ownership structures.
AI-generated analysis. How Rhea-AI works. Not financial advice.
